9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction

Men's urological and reproductive health encompasses a diverse spectrum of acute infectious, chronic obstructive, and vascular-endocrine disorders that significantly impact quality of life and longevity. For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification mandates expertise in managing Lower Urinary Tract Symptoms (LUTS) secondary to Benign Prostatic Hyperplasia (BPH), understanding the pharmacodynamics and PSA-altering effects of urological drugs, managing acute and chronic prostatitis syndromes while avoiding diagnostic pitfalls, differentiating acute scrotal emergencies (epididymitis vs. testicular torsion), and navigating the comprehensive workup and safe pharmacological management of Erectile Dysfunction (ED).

---

1. Benign Prostatic Hyperplasia (BPH)

Pathophysiology & Anatomical Zonation

BPH is a non-malignant adenomatous proliferation of prostatic epithelial and stromal cells. Intraprostatic 5-Alpha Reductase (Type 2) converts circulating testosterone into Dihydrotestosterone (DHT), a potent androgen with a 5-fold higher binding affinity for androgen receptors. DHT stimulates transcription of growth factors (FGF, TGF-$\beta$), driving cellular hyperplasia.

+-----------------------------------------------------------------------------+
|                        PROSTATE ANATOMICAL ZONES                            |
|                                                                             |
|   1. TRANSITION ZONE (Periurethral Zone)                                    |
|      - Surrounds the proximal prostatic urethra (5-10% of prostate volume). |
|      - SITE OF ORIGIN FOR BENIGN PROSTATIC HYPERPLASIA (BPH).                |
|      - Progressive hyperplasia compresses urethral lumen -> LUTS.           |
|                                                                             |
|   2. PERIPHERAL ZONE (Posterior & Outer Aspect)                             |
|      - Comprises 70% of prostate volume; easily palpable via DRE.           |
|      - SITE OF ORIGIN FOR > 70-80% OF PROSTATE ADENOCARCINOMAS.             |
|      - Palpable induration, nodules, or asymmetry suggest malignancy.       |
|                                                                             |
|   3. CENTRAL ZONE                                                           |
|      - Surrounds ejaculatory ducts (25% of volume).                         |
+-----------------------------------------------------------------------------+

Clinical Presentation: Storage vs. Voiding LUTS

+-----------------------------------------------------------------------------+
|                   LOWER URINARY TRACT SYMPTOMS (LUTS)                       |
|                                                                             |
|   STORAGE / IRRITATIVE SYMPTOMS        VOIDING / OBSTRUCTIVE SYMPTOMS       |
|   (Secondary to Bladder Response)      (Direct Mechanical/Dynamic Block)    |
|   -----------------------------------------------------------------------   |
|   - Urinary Urgency (sudden need)      - Urinary Hesitancy (delayed start)  |
|   - Urinary Frequency (voiding > Q2H)  - Weak / Decreased Urinary Stream    |
|   - Nocturia (>= 2 awakenings/night)   - Intermittency (stop-start stream)  |
|   - Urge Incontinence (detrusor        - Terminal Dribbling                 |
|     overactivity / involuntary spasm)  - Sensation of Incomplete Emptying   |
|   - Dysuria (irritation)               - Straining to Initiate Voiding      |
+-----------------------------------------------------------------------------+

Clinical Evaluation & Diagnostic Workup

1. International Prostate Symptom Score (IPSS) / AUA Symptom Index:
   • Standardized 7-question validated questionnaire assessing symptom severity (Score: 0–7 Mild, 8–19 Moderate, 20–35 Severe) plus a Quality of Life (QoL) bother score.
2. Digital Rectal Examination (DRE):
   • Classic BPH finding: Symmetrically enlarged, smooth, firm, elastic, rubbery, non-tender prostate with a preserved median sulcus.
   • Hard, stony, asymmetrical, discrete nodules, or loss of median sulcus suggest prostate adenocarcinoma mandating serum PSA and urology biopsy referral.
3. Urinalysis: Dipstick and microscopy to rule out hematuria, pyuria, and urinary tract infection.
4. Serum Prostate-Specific Antigen (PSA): Quantifies risk of clinical progression, acute urinary retention, and aids in shared decision-making for prostate cancer screening.
5. Post-Void Residual (PVR) Measurement: Bedside bladder ultrasound immediately after voiding. Normal $< 50\text{ mL}$; a PVR $> 200\text{--}300\text{ mL}$ indicates significant urinary retention / detrusor failure.
6. Serum Creatinine: Indicated if urinary retention, hydronephrosis, or obstructive nephropathy is suspected.

Guideline-Directed Pharmacotherapy for BPH

+-----------------------------------------------------------------------------+
|                        BPH PHARMACOTHERAPY MATRIX                           |
|                                                                             |
|   DRUG CLASS             REPRESENTATIVE AGENTS   MECHANISM & CLINICAL PEARLS|
|   -----------------------------------------------------------------------   |
|   Alpha-1 Adrenergic     Tamsulosin (0.4-0.8mg)  - Relaxes smooth muscle of |
|   Antagonists (Uro-      Alfuzosin (10 mg daily)   bladder neck, prostate   |
|   selective: alpha-1A)   Silodosin (8 mg daily)    capsule & prostatic ureth|
|                                                  - RAPID onset (48-72 hours)|
|                                                  - Does NOT shrink prostate |
|                                                  - Does NOT change PSA      |
|                                                  - SE: Retrograde ejaculat, |
|                                                    Intraoperative Floppy    |
|                                                    Iris Syndrome (IFIS).    |
|                                                                             |
|   Alpha-1 Antagonists    Doxazosin (Cardura)     - Non-selective; causes    |
|   (Non-selective)        Terazosin (Hytrin)        vasodilation & BP drop   |
|                                                  - SE: First-dose orthostas,|
|                                                    syncope, dizziness.      |
|                                                                             |
|   5-Alpha Reductase      Finasteride (5 mg daily)- Blocks conversion of     |
|   Inhibitors (5-ARIs)    Dutasteride (0.5mg daily) Testosterone -> DHT.     |
|                                                  - Shrinks prostate volume  |
|                                                    by 20-25% over 6-12 mos. |
|                                                  - Indicated for enlarged   |
|                                                    prostates (> 30-40 grams)|
|                                                  - HALVES SERUM PSA (-50%)! |
|                                                  - SE: ED, decreased libido,|
|                                                    gynecomastia, depression.|
|                                                                             |
|   PDE5 Inhibitors        Tadalafil (5 mg daily)  - Increases cGMP in bladder|
|                                                    & prostate smooth muscle.|
|                                                  - FDA approved for BPH + ED|
|                                                  - NEVER mix with nitrates! |
+-----------------------------------------------------------------------------+

[!IMPORTANT] The Mandatory "PSA Doubling Rule" for 5-ARIs: Chronic therapy with a 5-Alpha Reductase Inhibitor (Finasteride or Dutasteride) shrinks the glandular epithelial component of the prostate and decreases serum PSA levels by approximately 50% after 6 months of continuous use. When interpreting serum PSA in a man who has taken a 5-ARI for $\ge 6$ months, the AGPCNP must multiply the reported laboratory PSA by 2 (double the value) to obtain the patient's true baseline. Any confirmed increase in PSA while taking a 5-ARI (even a rise within "normal" ranges) is abnormal and mandates immediate urological referral to evaluate for high-grade prostate cancer!

[!NOTE] Intraoperative Floppy Iris Syndrome (IFIS): Alpha-1 antagonists (especially $\alpha_{1A}$-selective agents like Tamsulosin) block pupillary dilator smooth muscle receptors in the iris. Patients undergoing cataract surgery are at high risk for IFIS (triad of flaccid iris stroma, progressive intraoperative pupillary constriction, and iris prolapse). Patients must inform their ophthalmologist of past or present alpha-blocker exposure prior to eye surgery.

---

2. Prostatitis Syndromes (NIH Classification)

Prostatitis comprises a collection of infectious and non-infectious inflammatory disorders of the prostate gland classified into four major categories by the National Institutes of Health (NIH).

+-----------------------------------------------------------------------------+
|                        NIH CLASSIFICATION OF PROSTATITIS                    |
|                                                                             |
|   * Category I:   ACUTE BACTERIAL PROSTATITIS (ABP)                         |
|                   - Acute, severe systemic bacterial infection of prostate. |
|                                                                             |
|   * Category II:  CHRONIC BACTERIAL PROSTATITIS (CBP)                       |
|                   - Recurrent, relapsing UTIs with same bacterial strain.   |
|                                                                             |
|   * Category III: CHRONIC PROSTATITIS / CHRONIC PELVIC PAIN SYNDROME (CP/CPPS|
|                   - Pelvic pain/discomfort >= 3 months without bacteria.    |
|                   - Accounts for > 90% of all prostatitis presentations!    |
|                   - IIIa: Inflammatory (WBCs in semen/EPS); IIIb: Non-inflam|
|                                                                             |
|   * Category IV:  ASYMPTOMATIC INFLAMMATORY PROSTATITIS                     |
|                   - Incidental WBCs in EPS/biopsy without clinical symptoms.|
+-----------------------------------------------------------------------------+

Acute Bacterial Prostatitis (Category I)

• Etiology: Ascending infection of enteric uropathogens from the urethra or intraprostatic reflux of infected urine.
  • Men $> 35$ years: Coliform enteric bacilli: Escherichia coli (75–85%), Klebsiella, Proteus, Enterobacter, Pseudomonas, and Enterococcus.
  • Men $< 35$ years (or high-risk sexual behavior): Sexually transmitted pathogens: Neisseria gonorrhoeae and Chlamydia trachomatis.
• Clinical Presentation: Sudden onset of high fever, chills, rigors, malaise, severe perineal and sacral back pain, suprapubic ache, dysuria, urinary frequency, urgency, and acute obstructive voiding symptoms (hesitancy, weak stream, urinary retention).
• Physical Examination:
  • Gentle Digital Rectal Examination (DRE) reveals a warm, swollen, exquisitely tender, tense, boggy prostate.

+-----------------------------------------------------------------------------+
|                   CRITICAL CLINICAL WARNING: DO NOT MASSAGE!                |
|                                                                             |
|   Vigorous, repeated, or aggressive prostatic massage is STRICTLY           |
|   CONTRAINDICATED in Acute Bacterial Prostatitis!                           |
|                                                                             |
|   Pathophysiological Rationale: Compressing the acutely inflamed, infected   |
|   prostate forces live uropathogens into the prostatic venous plexus and     |
|   systemic circulation, precipitating BACTEREMIA AND LIFE-THREATENING        |
|   SEPTIC SHOCK!                                                             |
+-----------------------------------------------------------------------------+

• Management Protocol for Acute Bacterial Prostatitis:
  • Outpatient Mild-to-Moderate Coliform Prostatitis: Prescribe oral antibiotics with high lipid solubility and excellent prostatic tissue penetration for 4 to 6 weeks (prolonged course required to sterilize prostatic parenchyma):
    • Ciprofloxacin $500\text{ mg}$ PO BID $\times 4\text{--}6\text{ weeks}$, OR
    • Levofloxacin $500\text{ mg}$ PO daily $\times 4\text{--}6\text{ weeks}$, OR
    • TMP-SMX DS 1 tablet PO BID $\times 4\text{--}6\text{ weeks}$.
  • STI Prostatitis (Age $<35$ or high risk):
    • Ceftriaxone $500\text{ mg}$ IM single dose PLUS Doxycycline $100\text{ mg}$ PO BID $\times 14\text{ days}$.
  • Acute Urinary Retention: If the patient develops acute retention, transurethral Foley catheterization is contraindicated (causes severe pain and risk of prostatic parenchymal disruption/sepsis); place a percutaneous suprapubic catheter instead.

---

3. Epididymitis, Orchitis & Testicular Scrotal Emergencies

Acute Epididymitis is an inflammation of the epididymis resulting from retrograde ascent of pathogens from the urethra or bladder via the ejaculatory duct and vas deferens.

+-----------------------------------------------------------------------------+
|                 EPIDIDYMITIS ETIOLOGY: AGE-STRATIFIED MATRIX                |
|                                                                             |
|   AGE GROUP / POPULATION      PRIMARY PATHOGENS       GUIDELINE REGIMEN     |
|   -----------------------------------------------------------------------   |
|   Men < 35 Years              Chlamydia trachomatis   CEFTRIAXONE 500 mg IM |
|   (Sexually Active / STIs)    Neisseria gonorrhoeae   single dose           |
|                                                       PLUS                  |
|                                                       DOXYCYCLINE 100 mg    |
|                                                       orally BID x 10 days. |
|                                                                             |
|   Men >= 35 Years             Escherichia coli,       LEVOFLOXACIN 500 mg   |
|   (Coliform / Enteric / BPH)  Pseudomonas, Klebsiella orally daily x 10 d,  |
|                                                       OR OFLOXACIN 300 mg   |
|                                                       orally BID x 10 days. |
|                                                                             |
|   Men Practicing Insertive    C. trachomatis,         CEFTRIAXONE 500 mg IM |
|   Anal Intercourse            N. gonorrhoeae, PLUS    PLUS                  |
|                               Enteric Coliforms       LEVOFLOXACIN 500 mg   |
|                                                       orally daily x 10 d.  |
+-----------------------------------------------------------------------------+

Clinical Differentiation: Epididymitis vs. Testicular Torsion

Testicular torsion is a surgical emergency characterized by twisting of the spermatic cord, compromising venous outflow and arterial inflow. The AGPCNP must rapidly distinguish torsion from epididymitis.

+-----------------------------------------------------------------------------+
|                   PHYSICAL SIGNS IN ACUTE SCROTAL PAIN                      |
|                                                                             |
|   [ PREHN'S SIGN ]                                                          |
|   - Technique: Examiner gently lifts the affected hemiscrotum toward pubis. |
|   - POSITIVE (Pain decreases) -> Supports ACUTE EPIDIDYMITIS.               |
|   - NEGATIVE (Pain persists/worsens) -> Strongly suggests TESTICULAR TORSION|
|                                                                             |
|   [ CREMASTERIC REFLEX ]                                                    |
|   - Technique: Stroke the superior-medial thigh with an applicator.         |
|   - Normal / Intact -> Ipsilateral cremaster muscle contracts (testis rises)|
|   - PRESERVED -> Supports ACUTE EPIDIDYMITIS.                               |
|   - ABSENT -> Pathognomonic hallmark of TESTICULAR TORSION.                 |
+-----------------------------------------------------------------------------+

---

4. Erectile Dysfunction (ED) & Hypogonadism

Pathophysiology of Penile Erection

Erection is a neurovascular event initiated by sexual stimulation:

1. Non-Adrenergic, Non-Cholinergic (NANC) neurons and endothelial cells release Nitric Oxide (NO) into the corpus cavernosum.
2. NO stimulates soluble guanylyl cyclase, increasing cyclic Guanosine Monophosphate (cGMP).
3. Elevated cGMP lowers intracellular calcium, producing smooth muscle relaxation in cavernosal arterioles and trabecular meshwork.
4. Engorgement of cavernosal lacunar spaces with blood compresses the subtunical venules against the rigid tunica albuginea, trapping blood (veno-occlusive mechanism).
5. Detumescence: Phosphodiesterase Type 5 (PDE5) hydrolyzes cGMP to 5'-GMP, leading to smooth muscle contraction and venous outflow.

Etiological Classification of ED

• Vasculogenic ED (70–80% of cases): Atherosclerosis, endothelial dysfunction, hypertension, diabetes, smoking, peripheral vascular disease.
  • Clinical Concept: "The Artery Size Hypothesis" — Cavernosal arteries are small ($1\text{--}2\text{ mm}$) compared to coronary ($3\text{--}4\text{ mm}$) and carotid ($5\text{--}7\text{ mm}$) vessels. Vasculogenic ED is an early surrogate marker of occult coronary artery disease (CAD), preceding acute coronary syndromes by 3 to 5 years!
• Neurogenic ED: Diabetic autonomic neuropathy, radical prostatectomy (cavernosal nerve injury), spinal cord trauma, multiple sclerosis, Parkinson's disease.
• Endocrine ED: Hypogonadism (low testosterone), hyperprolactinemia, hypo/hyperthyroidism.
• Psychogenic ED: Performance anxiety, depression, marital conflict. Hallmark: Sudden onset, situational, with preserved nocturnal and early morning erections (which are absent in organic/vasculogenic ED).
• Medication-Induced ED: Antihypertensives (Beta-blockers, Thiazide diuretics, Spironolactone), SSRIs, SNRIs, 5-ARIs, Antiandrogens, H2RAs (Cimetidine).

Diagnostic Evaluation & Testosterone Testing Protocol

1. Cardiovascular Risk Assessment: Stratify using the Princeton Consensus III guidelines before prescribing pro-erectile drugs or clearing for sexual activity.
2. Serum Testosterone Evaluation:
   • Testosterone exhibits significant diurnal variation (peaks in early morning).
   • Measure Total Serum Testosterone drawn in the fasting state between 8:00 AM and 10:00 AM.
   • Confirmation Rule: A low testosterone level ($< 300\text{ ng/dL}$) must always be confirmed with a second early morning repeat fasting sample plus Free Testosterone, serum Luteinizing Hormone (LH), Follicle-Stimulating Hormone (FSH), and Serum Prolactin to differentiate primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism.

Stepwise Management of Erectile Dysfunction

+-----------------------------------------------------------------------------+
|                        STEPWISE ED MANAGEMENT ALGORITHM                     |
|                                                                             |
|   STEP 1: LIFESTYLE & CARDIOVASCULAR MODIFICATION                           |
|   - Smoking cessation, weight loss, exercise, glycemic/lipid control.       |
|   - Review and substitute offending medications (e.g., switch thiazide to   |
|     ACEi/ARB; switch SSRI to Bupropion).                                    |
|                                                                             |
|   STEP 2: FIRST-LINE PHARMACOTHERAPY (PDE5 INHIBITORS)                      |
|   - Sildenafil (Viagra): 25-100 mg PRN 1 hr before sex; duration 4-8 hr;    |
|     take on empty stomach (fatty meals delay absorption).                   |
|   - Tadalafil (Cialis): 10-20 mg PRN or 2.5-5 mg daily; duration up to      |
|     36 hours ("weekend pill"); absorption unaffected by food.               |
|   - Vardenafil (Levitra): 10-20 mg PRN; Avanafil (Stendra): rapid onset 15m.|
|                                                                             |
|   STEP 3: SECOND-LINE THERAPIES                                             |
|   - Vacuum Erection Devices (VED; constriction ring max 30 min).            |
|   - Intraurethral Alprostadil Pellets (MUSE).                               |
|   - Intracavernosal Injections (ICI: Alprostadil, Trimix; risk of priapism).|
|                                                                             |
|   STEP 4: THIRD-LINE SURGICAL THERAPY                                       |
|   - Inflatable Penile Prosthesis (IPP) surgical implantation.                |
+-----------------------------------------------------------------------------+

[!CAUTION] Lethal Drug Interaction: PDE5 Inhibitors and Nitrates: Co-administration of any PDE5 inhibitor with Nitrates (e.g., sublingual Nitroglycerin, Isosorbide mononitrate, Isosorbide dinitrate, or inhaled alkyl nitrites / "poppers") is ABSOLUTELY CONTRAINDICATED.

Mechanism: Nitrates stimulate guanylyl cyclase to produce massive amounts of cGMP, while PDE5 inhibitors block cGMP breakdown. The resulting synergistic cGMP surge triggers uncontrolled, profound vascular smooth muscle relaxation, resulting in catastrophic refractory hypotension, cardiogenic shock, and fatal cardiovascular collapse.

Safety Clearance Windows: If a patient on a PDE5 inhibitor develops acute coronary syndrome / chest pain:

• Nitrates must be withheld for at least 24 hours after taking Sildenafil or Vardenafil.
• Nitrates must be withheld for at least 48 hours after taking Tadalafil.